Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
| Autor: | Salehi, Mohammadreza a, ⁎, Alavi Darazam, Ilad b, c, ⁎, Nematollahi, Alireza d, Alimohammadi, Masoumeh d, Pouya, Sedigheh d, Alimohammadi, Reza d, Khajavirad, Nasim e, Porgoo, Meysam d, Sedghi, Mosslim d, Mahdi Sepahi, Mohammad d, Azimi, Maryam f, Hosseini, Hamed g, Mahmoud Hashemi, Seyed h, Dehghanizadeh, Somaye d, Khoddami, Vahid d, ⁎ |
|---|---|
| Zdroj: | In International Immunopharmacology 15 June 2024 134 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect